Indivior PLC (INDV)
NASDAQ: INDV · IEX Real-Time Price · USD
17.04
-0.30 (-1.73%)
May 17, 2024, 3:02 PM EDT - Market open
Indivior Revenue
Indivior had revenue of $1.12B in the twelve months ending March 31, 2024, with 18.57% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $284.00M with 12.25% year-over-year growth. In the year 2023, Indivior had annual revenue of $1.09B with 21.31% growth.
Revenue (ttm)
$1.12B
Revenue Growth
+18.57%
P/S Ratio
2.09
Revenue / Employee
$965,636
Employees
1,164
Market Cap
2.30B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.09B | 192.00M | 21.31% |
| Dec 31, 2022 | 901.00M | 110.00M | 13.91% |
| Dec 31, 2021 | 791.00M | 144.00M | 22.26% |
| Dec 31, 2020 | 647.00M | -367.00M | -36.19% |
| Dec 31, 2015 | 1.01B | -101.00M | -9.06% |
| Dec 31, 2014 | 1.12B | -101.00M | -8.31% |
| Dec 31, 2013 | 1.22B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Patterson Companies | 6.57B |
| CONMED | 1.26B |
| ACADIA Pharmaceuticals | 813.81M |
| NovoCure | 525.66M |
| Vericel | 207.78M |
| RxSight | 101.10M |
| Rhythm Pharmaceuticals | 91.93M |
| Janux Therapeutics | 7.29M |
INDV News
- 22 days ago - Indivior Announces Q1 2024 Financial Results - PRNewsWire
- 2 months ago - Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone - PRNewsWire
- 2 months ago - Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation - PRNewsWire
- 3 months ago - Drugmaker Indivior consults on moving primary listing from London to US - Reuters
- 3 months ago - Indivior Announces Q4 / FY 2023 Financial Results - PRNewsWire
- 6 months ago - Indivior Announces Q3 2023 Financial Results - PRNewsWire
- 7 months ago - Indivior to pay $385 mln to end Suboxone monopoly lawsuits - Reuters
- 7 months ago - Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals - PRNewsWire